HUE028595T2 - Nitrogéntartalmú aromás heterociklil vegyület - Google Patents

Nitrogéntartalmú aromás heterociklil vegyület Download PDF

Info

Publication number
HUE028595T2
HUE028595T2 HUE09794416A HUE09794416A HUE028595T2 HU E028595 T2 HUE028595 T2 HU E028595T2 HU E09794416 A HUE09794416 A HU E09794416A HU E09794416 A HUE09794416 A HU E09794416A HU E028595 T2 HUE028595 T2 HU E028595T2
Authority
HU
Hungary
Prior art keywords
group
compound
mmol
added
reaction
Prior art date
Application number
HUE09794416A
Other languages
English (en)
Inventor
Keiko Suzuki
Takahiro Yamaguchi
Akihiro Tamura
Tomohiro Nishizawa
Mitsuhiro Yamaguchi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HUE028595T2 publication Critical patent/HUE028595T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (7)

  1. t ¥«#iíleí, msaáy&t feövetfee# Äalfeöos M0& {1} w jp|gf$*«#sä$fef' slthgadhsté ¥às
    érni á feá!##*: X-«fe p&amp;toHI csapósl, is X s«4&amp; 8#A; vs# A Ä&amp;tvs:)C-«i 0^Ê ssöpoft, k* mmà.mptxt* ksâmxMëâ m^n, tmmM&amp;wmn,. Μή&amp;$βί0 mïpœî i Äly fel m ^kmm m&amp;wmmmq&amp;im is m»pík # «S|gsÄd feli <is<spöíí, s^bsststÄ fsat Ssegört, «hol U mim ®m&amp;sM fel *m yémm cmpanbóí «, * «így á-ta# mm- hrnmem ¢5SÓJSöíi SbMIÉ £* VS|y Ő-íagÖ *f»más bfB#eÍfeSÍ SS(pi Ä ft SHMÍNÍ«(«ty i "4 srnpm í%gsife;Ml fel mi \iámm issàSÂeiïS öSöpöstfeÓl «* fsai liüyCfe áfesl) esoporfe &amp;ub$sâM$ M <€r (¾ a&amp;B} ssöptsri, edíól szstoitaeasies.) »* mm ^gptí&amp;A M vm ÄW ssötófeam c#pöílbél S·· vsp :<Nagw ajOű&amp; ls«^Síkfe|S4*C* slki!) ssöpöít:, mgy mh&amp;äk&amp;t 5* m# S4agâ smsíás S«ïÂfeit]{Cî»es slkilj «sepsfst, aöM #*ί*Μΐ&amp;ΜΜ^ M és^a»t. %^ISótó: Β » «»: ssäteifesfefe* çsûpafthôl * m a U, va# 3, η Ον«# *, faMve, feo#Mtn 3, s % &amp;4> ^.¾¾ Rr itaii^e^äs. iS^fetóí C^CS slkS cí»p?t Mo0m^&amp; íMíesí^oít litor^spsrt, C^alfeöxicsöpä^^gy i^ogéa csoport, B Ähi csoport, sæoMMiimftfeii ssspc^ stó » ssÄigtssßaCsfe) 1-4 «soptffe mmly ÄgpfaSl M «p.'^tety« »!Ä®«pM ^ vegs HHagö aromás fcë^lfeig <®ψ®,: saateM ¥~ y&amp;gy i(¥fc# ówöbs«» 5«»Ä1 Ä? * ·8?»1&amp;$χί1κ»8^' W cs#otl s??*äiy i%g«ifcsSI fei ym ssfepspivs mpöáé# '&amp; va# mposm feOvoteO feéplsi (SI) rpprsscífe&amp;ga
    afeol δ-’ és |f plÄgy&amp;s %gSSÄ? feiî csÈp^.:si^^t fc»U ftsogfttfe ahoi A 14«νι^*μ$ t®g«^ JtihP *δ®8&amp;»: csoportból % 5-vagf »* csapit, vagy ssäibssÄ s- vs# 6-ugó wwoâs tettmxMil empan, *£#« sïsMsuej^s^ 1-4 *m? mggsâssüM ms mmmmmmm^ U ssM^i®fess«s «sö|5<st ö .mqtâfy #»# # fegvsifeeÂfeôi; C^Qs alkil SSógáíg MçlrpxiliA-C« aildl) ssaporfe m<mMCr%* Ä1) csapa^ διΟβ|^(€^ agd!) mpm, '^C% cifelasifeli^ €Α O&amp;Iös&amp;ücselest, ßr€*ternitepsit. CrQ. siklód ««open, ötekl csopte €V€$ altat «Söpört, hsk(§é((CrQ «fal) csoport, CyC* «Ikötkt csoport, CrC« stótolM osöjs0¾ Cj-C» «aktelfoal «opte teáp csoport. í'í*Cs tekrte csoport, ^(€(-1¾ älkiljarsisss <ssöp% testete ssépp, #v-€«, tei}kteoatete -mipeá, (SVC* MW (Çj^s «opta tel! «soport, iCrQ sllílite^sai! «sppprt, ksrtat csoport, feil« tek!)!có?tall csoport, kte»|i coopork (Cyc< ÄiMdNMA*i export, Ætï}m(mk$é<$nî} csoport, ataoszulfOm! «söpört, (CrQ -m&amp;sá, a^SrC* mpm etette®*. te> esopo«, «s htepsosopte 2. te h igtei**» teíiii vegyül«! sorsak ^^ÄäsäÄg tepdkte te amelyet » kövte^SlÄss ΙίφΜρΐ) spprs^l
  2. 3. Ax U sgésrypoot ssaiot! yegyta vagy »mmk .tegvsctesxetlleg elfogta*^ sója, amolyet « MyteM Stetes M0i :|ΐ*2) ^ps^asÄ
    telít** kiá^ntem Cr%> slkl! csípős, tete»(Cr£* tel! tepte $ír€s ρϋ® osspört, ^k8) €r<% teoÄI tepte Srtetemil (Söpört, €~€* alkirill esöpört, €)-€$ ÄSsasItei! tejte* feróál mopori (^^»Am^sieéb^ csoport, tete*5®* »prfe |€Γ€*. äskHspsso^tessit csoport, 4$Ct*C&amp; csoport, ssRipmjIlposI mgmfc. (€ä*€* Ältetetetet csoport, vsgy $(£<*£* teöte'ae^fößii «sofort, tetepk !?* ilggtteäM teC* ÄS cssööort, φΜ) -mmm. <€*€* Cj~Cs dkloste csoport. CrC<( steril esoporl, teC« slkte csoport, MMrom £**£« aterä tepöil Steil csoport, |CpÇ* aikSlktete esoptsst, da» csoporti, vagy tkksgáfi ßsopört, és k kivagy2. 4. Λ 3, Igésypom steaii vKgySiot, yagy sósak gvé^^s^tslőf altbpádsíö δφ» «bol Márogéo a&amp;Ä «ste**> <*¥% oidps!kdH^5"Q^k^«Sö|?wt hs!ogte&amp;s*£? te!) csoport, Ote teptel eseperk Cj-C* altat csoport, vagy Cj^alklsM csoport, Φ Cröxtm mm> häfegmßrts mm mm' $ ~5 csoport ,. ajod? ki vsa y#ssääR* « cssspönbdk totof M kövsitoiäliÄ fiús# esopött ás kto oppört, €ÄeliÄilcsöp^ cíétmmm nmmpomys^ klár «ζψΜ, μ \ k vggîf i. 5, A '&amp; iglîîj^snf sgerkti vggysto vsgjjr sassk gÿé^'si^ssk^^ë clf«g&amp;Ä*&amp; s$&amp; 8&amp;# *** €(-¾ mm csoport, ás k 9. &amp; Ä® Igéöypösxí: S^Hsíi vegyik* 3 vsgÿ ÄSk gk^gp^í^Kskteg slggsÂsié söjg, ahol R?s §g! csoport, « k ö. % M 1. $gs&amp;«^pst sarkai «©Λ :W$$ afusak’^vigpas^ssikeg gifôiiÉ&amp;tè séjs, sspclyet «
    she*-Φ iigk|CrC2 aikl) mpm vagy #11);: mm·. *M- ® sa&amp;sgtrtusnaiek) 1-3 csoport, &amp;««lv IlggáfeSi: tó* vákssxtvs ís ssifegö^^i·«1 csopcat, æfiôlg# k$\$!|«aÖliMfc :CrCs sÜ mm. ka&amp;#«#r % àkk s Megárt mpMták) í«5 nsopm;m^ '&amp; vü Plas^ya, a es^sö#éi smfy II követkessőtósókÍkpr-í9«föa*:)lg kiér csepeg ílsto ««open, és Iád? sagest '$*  % Ii&amp;s#e8* sajtol valaki vagy mmk shöf •E* Μ*®!! esope** vagy sætesgMi értilmglö csoport, sSké s sM?agkIs®J^sk) 1-3 mpm &amp;gipte$ » amel* ki vsa v&amp;säfvs telrfk&amp;ns osopr&amp;to s2, &amp; ssæâ^rtèise® m&amp;m «2 »rnmmtym Mvm&amp;ßm'. mM: csep»*, tífisospeiS csoport, ás, íkor csoport % As I igénypont smm. yégpSet ysgy *xtm&amp; gyógysmlssstil«§ ëh§mm- s#k m*km g kavctksgê IM&amp;JOS tóflsi (Î'I) fcpragsaill
    1% -te i - ig^^iHsksgsîlàïl yggÿiysï ;¥δ$^ ásnák gy^gypsvrisctoiiog dJog&amp;cliskö sója, sanely«? s
    {crc* atonal ·*&amp;# wä Mi«g«siCCj^ ÄilJ «sofort Cs«Ö4 sikkÄst «scprik Cr&amp;t steil essest vsggjf Cj-C* sMßlS . j« Sv .«14k iVlvà ' CkOpOtt. U< à 1#, äglsypoßi iípfössl: vçgpsie*' 'W®#: SíáKÉ'· ^fessáháíá: ölssl &amp;** Q*ß* &amp;É? «Sispostv Ά A&amp; I- i !, igénypontok bâm^pœ- smkâ- vegyffe vagy Ä $ytyytmémék&amp; «MpMfr sójáéból ,R; tebsss ssöisíjst, B< .fe Nîl. |&amp;îypte fcfeoslyiks szüM **!§&amp;&amp;&amp; vagy aaskk Mpeé»üÍ(í elfepáte si, sfelámgéí^^ CrCjsim^ hætegênfCr CsÄïrnimh aisd s teg&amp;i^rnmmM Ή «spwfc Μ mstvrnmm t^?s*^»i«aefy'P köveisaitMii flösf esoposi és mos^m IA> Az 141 sietek Mï»!ylk&amp; mskú vsgyÄ i**gy a«i g^ps^tósseöfcg elfopáte sofss* sliöí &amp;* It5, -R5, és f* j$«á«gyie íö*get!e»üi Msfrsgés *œ» vagy «bőttaKpát
  3. 15, Az hm. i^pmm |áfSí#5te stósís ^gplst vagy »mák gyó^mré:teleg eifegsálaté 0jâ, Sfeïl ïôîsd%ylks %iea«a8í Βώχφϋmem· vagy S«#é«^*ö)í&amp;..é8 mkäm$ks hiîÙOgés ate, Μ» A® í 4$,. î^énysmîtik feáaaeSysks *a«s®8i vggylttat vagy p&amp; tyègyss^s«eip®g «llopteö s6ja. ahoi B saisi «sos»** y«gy: sæüteiîàâii: oaÉfói «Síp^ afcæî s ?>f ssepon fSgg?Ö«sSl, msày kl vss vâlteva §x«ltetes ssoprs&amp;ô! «3, #. ste&amp;Ptea ip «3 s «apport, assdy &amp;i feSv^sMMi::·£*Α φΜχ^φύ, bstagàpCr €·> ûM). s«ûp8fi* shol s haiogés aasspai^ :H WPQ&amp; as8$5f &amp;»*** visssæïya #«%# :k$yeteôk^ ksôr «sepert, htexicso|îe5t, CrC>. dkoxt ««po«. ite asopan, <ks korcsoport 1% te \-m igésyptek Istelÿto wîM vsgyStet «sf «Ä gy^as^sásíiteg d&amp;gsÄO sops, ásíB «sopostoî a következő képki(ite) r«prsste|ia
    skaï B* &amp;»li s^testÄ fèsJI «sob®&amp; g sísí^SíSsíscss^ l# esepos* g^ggetlesül., amely M vsa válásivá «kôlassÉfeeos cat$®tè&amp;i φ> S>tagá :8Ä&amp;s htststodklll cstspojt, vsgy aai&amp;Sïliïs SAágó esopa^ ÄI a J -3 mpm Wÿ^faM-, :$®φ kl vas väte» 'Sa^fcssaSfeM». csrpssiW Ä B-* feil «ssop% MM «bel &amp; l*$ tmm ffiggMM* sîssly M m ää .trtwÄai esopÄt s4 pÄI ssepO. vs# :sæ&amp;s»8sM pÄ «sop^ äisöl a febâxiMa^ak.i Kl asaprl afelÿ iis Va&amp; Mitüt sfessaifeas MM» «sefs®»: -a4· &amp; '«stí|ía^. asiseSy IÉ SsÖvMMlMIl 0: -¾ Ml «sp«t M^ft{C. -Cs MO ®^pä% f€r&amp; eitósÉÉK^A #®> <$ΜΚ* CjCs Mö&amp;M «feSört, CrC* älkssNs#^ Ssmil mpst, (¾¾ #C|fe#pli mpsst, desm'd^m, ihm siûpùti, kié? «sep«, és mim csàpâé, és $»MMssn$ .«Μ # a csföpíss, amely kl! kPafesÂ# OrC*. älkk ssspmi, M^&amp;sCOrO* Ä) sssprO M&amp;mà mp^% Ογ€4 a3ks*i s^k# iawsaa^p:, brfe csoport •'IS;. M MS. ipl# slfcgsdfeê $φ, si# P csoportot «K feofelfeS 0¾ sepeM1#1
    si# Bx* *btro#ferpss&amp; 34*0 éM kfeioeltóp smpmi v»gy miï&amp;Êôtèk »««^jénteitebntt.^âM Mk-lsaseSiiM. ahol a $2#sfe.fep{ek> 1 vegy 2 «sopon ibggetterâi M si va» vâlppvs .a^fe^stfess «opposé B  Ml mspm> Mp®, Ml $:ρώ*Μδβκ$(9^ I vsgy 2 esepït IliggeSimSl, feely 11: va» vfesætvs sm^Pfeas esogertóö?; pÄI csefet vagy möbsPiaält pMèli «sepri, âi&amp;î s SÄüBsKÖöjeKsisk) 1 vsgv 2 csefpé«' &amp;/&amp;&amp;&amp;&amp;, *mly M: vas vâlssPvs sPbsPtfe&amp; csoporti# «7, sPkfetmcns msp&amp;ti ®ô « fefet, wœ$$ iîi k8feks*^Ä CrC4 alkM esôpori,.. iglÿpsÎCî'-Oj alksi) csoport, æbel a àalsgÉ* çspôf?(ôk) («5 «sepert, amofy ÎÜ va» v&amp;làsaîva s csôfPk!#. fesly &amp;8 kfesfegbklÄ Bsor «söpört és klfecsoport, (€^4¾ skleaMHCrCj Ä«) csoport* Os A eMoa&amp;ll (€jÆkÂOkar&amp;«sfi «sc##, atom. csoport, Iteíípepö^,® klèî assp<M, és mihMhums esöpsrt Φ a csoport sofev síi kOveikerôM#: CrCj alkii e$oï>on> brtinm csoport Puprcsoppjfe Mór csoport, IS. Λ2 MS. igôsyi&amp;sotok hfesoiÿika sæm# vogylfe. vagy aapsk &amp;yögysofes-fekg eifopsksiS
    Ml pis csoport Μ » válásaivá a kôvetfeçë crt#srtfeél vagy feport, amely P vm vite**« a teM aW a ssafeÄiass egy esp«P, sspsly |%gktlp§(ki vsai 0ímm mÈæt&amp;m$ MippMÎ M
    saufes«Ütiä«ns ssoprt φ &amp;%mspQft emaly ál kiHpk«ESkB&amp;k ^rC* Äk£pp*k kateg&amp;?{£:~ Ck Ä1) cse&amp;ott, almi s fe&amp;ípgfe .csty«t^^ |*$ esöfiösi, amely kf sáa v$£agj$i$ ä eppóííbék ps&amp;íy Aü ^yd&amp;$2§tdï$! Biiöf eSíJföst &amp;i kiér essport, etllopss^ü esepíkk Á^&amp;tlksrWm! csöpög stgso «söpri, i»esí^?áés ä «sepert, 2¾. M W&amp; spR^»k feteöeívfe mmâ Ϋ*$0® '^ψ *&amp;&amp; iPgpm^pB5ég élÉpás# &amp;&amp;!&amp;> Μ Β ssopriot § S#eaík®pMgfei ÖSi); rpr&amp;æÂts,
    ^í«i B!s ésöpftli v« váltévá « kävstk«2$ αρρή&amp;Μ vsgy easpest, a&amp;seíy isi va» válaMys* pvsipp PsöpríMi fs sMssxííMk, &amp;h&amp;] *. s«^«ke«ms agy «soparîi mtèk? Bi^sBsns? kl vsa S£öbS2ti»i§ «ssprâséï s£
    As: s«pspttt«ï»ssttj>îst ix§ « ^pep sasaly AB feBveik«pkbëî;: mp# esoport, s*s cs«pöft, «s klór csoport. ti, M L igénypont sssmti vegyük* v&amp;gy a»nak gyAgys««rAms:í% elfogadható sója, amely kl van ygasEíva a csopprlBAÎ, «Rely àll s ksvefetökMÍ: •^|2hí^4í4^te0^^^-4H^I|sss«WM«^^-ilJpro^no!i>emii^o^í'^||ifili,Pö!»á-'kaaEfes®íáíiNSí^ 4· (3-|;4-k^r'<4-Miáro^^©n^>ía:ö>i«^Í^-kt'Íp?í>psríOít>Síisíy4í>^ I ~e%|rrol-3 4wBokilSks<i #» |3-f^*^Íiv{4~biörfexsífe^i)sx<»í&amp;aöí.'S't!lpri>vírííi<íj ;} mjfàfc· | ~ed Sj$m&amp;sS4s&amp;tt:b&amp;dBsy; 4* 34(4··&amp;Μ&amp;1§κη1}4^^ aísiss>l ^jfplô*4*3 ^ksrboAay? 4<·:Ρ"Ρ^Ι*^{44\^^>ί^8Β)1^δ^Ι-3^0'2^^®80φ^^0ΐ|^Η0ΐ0-!ί^ίΙ^ΐΓόΙ4·<1<^βΧΚδδν; 4- (344ékíbf*3#*biÉms&amp;k1^ l^lpinsl^ksffeôîïMsa^;
    3-Îl0O^m|^ô^^ÎïîO'i^ï%iè^t-34issfei>ïcûs3;v; és
  4. 22, Gyógyszerészi me&amp;zte®, wmiy. l5&amp;îés«ys| íamimaz *«. Igásyposíök bSto#Íe m0m ^mmm 33. Λ 22, ïgéB^fesî Sksrkbi \mm>^k Mmstôêâm bsps^pstak, appâte»»» «tôÂMs^ssmviiim,. snerbskferöíss. vagy II tlpasô àisb4?ss mellkas k««eîssèfce» vagy jksilaxiaâfe 24. A 2&amp; îÿkypm Mmmüàm kssalPta vâ|ÿ pbSlmlsébss. 25v A '22. tpsypsi mê^i hsmpotkkà, ^0:-m&amp;à>sÊmfat· mwtMm *mtm$m Mgfp-ôfllaxMhsït 23. A 22-.: igppest S®e#ks kanadaié, Mbäsaakksm h|5èîtî%&amp;«ÂSife vsg£ iktbkMisfes steatohspainis kfczaiàsèbsa. y®·· pTiâlîsxssâbaa, '2?, Âz 1*21 %á»yp«iÉlt ysgy jssmk pbpsgpksspkg slfögÄabä sôf» SkasâââiSïs blpsfjjpSsssk, áfeHpkkbks, lfÉi^afeoüa^«s spi!k&amp;.;æ$i^kâpâ^. vagy M pásé M .M %*á% igáppbbsk bámsíy&amp;e smtMi vsgyikä wi$&amp; sója feLbssxwÄra sfsbpîés ïæm^feessî vagy 8f5>Slasts#sH. .#, Ακ ί«2ί. %éap<p«ök MEskjyj&amp;e fesifM VbgyÄk vagy «safe gyôgpægÂstifeg eJfepábssb 3{j. As i--21, igpypbtbk b&amp;rsisslysk« ssapbti vagybkv vsgy sœak gydgpÄässstifeg gl&amp;gsdkab? séjs. »assptes Mps^ßssä^M< vagy baÄ&amp;PÄs *i»é^Â' k«2$l&amp;#«« vsgy
  5. 31. As 12 L %&amp;3ypo»tök bkmsslyike sasdott v$gpÄ mg$; asjaik äpbg>^e^®®däeg elfögadhs® sója r«lh8»s}5steag><0gyssofk«at
  6. 32. As 1-21. Igéayponiçk feéftîslyiks sxsrkb vegyUJ«* vagy amnak gyégysgæréssgîileg vlfogaáhaíö sà}&amp; MmmsÊkk-Mÿ&amp;mr «IMiiMsPan ftlhassnálásra blperflpkktsma. Äspidmia, îpb ^®t8^s»:is Asvmau sAsnvsklvrvxk vagy Ίϊ íjpsS bisbvte mvlHms ksssMsbbva vagy pmfíía&amp;tsábsm. 33. M 1-2 k igésypöaíok bármelyike ssedaíí vsgylikk vagy srnsk gyógysseíVsmüsig ç]%yvibaîà sáp foShasanklása gybgÿsser sióálibáxáb&amp;nfatbasgaáiásra dislipistea k«*ates*b«» vagy profilaxisában.
  7. 34. At 14í. %4ftjp«kok bäravbvlka szsÉaÜ «egytübf vagy ássák p%yssékésb8dl«|; elíbpáptb sója MkassnédAV gybgys&amp;v· gidállMsáb«.« %>í<i ssaíshöbssnjs akvaítóí 33. A*: í*21 ípRyfbbíok bánjpyíí® sxarM vsgy$<$ vagy «Ä gy^s^pspbieg dfejpíteé sbjjg PbssæaÂss lyègyyrsf ÄSMsärs Mprtsígtlm'yéöík vagy nemslkobylos si&amp;atöppatb&amp; kspéafe vagy pjysfcNbas.
HUE09794416A 2008-07-08 2009-07-07 Nitrogéntartalmú aromás heterociklil vegyület HUE028595T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008178377 2008-07-08

Publications (1)

Publication Number Publication Date
HUE028595T2 true HUE028595T2 (hu) 2016-12-28

Family

ID=41507085

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09794416A HUE028595T2 (hu) 2008-07-08 2009-07-07 Nitrogéntartalmú aromás heterociklil vegyület

Country Status (25)

Country Link
US (2) US8648103B2 (hu)
EP (1) EP2308838B1 (hu)
JP (1) JP5461398B2 (hu)
KR (1) KR20110025742A (hu)
CN (1) CN102149680B (hu)
AU (1) AU2009269178B2 (hu)
BR (1) BRPI0915473A2 (hu)
CA (1) CA2730078A1 (hu)
CO (1) CO6341610A2 (hu)
CY (1) CY1117503T1 (hu)
DK (1) DK2308838T3 (hu)
ES (1) ES2566529T3 (hu)
HK (1) HK1155443A1 (hu)
HR (1) HRP20160236T1 (hu)
HU (1) HUE028595T2 (hu)
IL (1) IL210498A0 (hu)
MX (1) MX2011000044A (hu)
NZ (1) NZ590790A (hu)
PL (1) PL2308838T3 (hu)
RU (1) RU2481330C2 (hu)
SI (1) SI2308838T1 (hu)
SM (1) SMT201600119B (hu)
TW (1) TWI435875B (hu)
WO (1) WO2010004972A1 (hu)
ZA (1) ZA201100183B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149680B (zh) * 2008-07-08 2014-12-10 第一三共株式会社 含氮芳族杂环化合物
EP2719690A4 (en) 2011-04-28 2014-12-31 Japan Tobacco Inc AMIDE COMPOUND AND USE THEREOF IN PHARMACY
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
CA2891208C (en) * 2012-11-12 2021-06-08 Victoria Link Limited Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia)
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
SI3464271T1 (sl) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kot inhibitorji plazemskega kalikreina
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2006427A3 (cs) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
CN101056635A (zh) * 2004-11-04 2007-10-17 默克公司 烟酸受体激动剂、含有该化合物的组合物及治疗方法
EP1811996A1 (en) 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
WO2006057922A2 (en) 2004-11-23 2006-06-01 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
GB0503053D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0505735D0 (en) 2005-03-21 2005-04-27 Glaxo Group Ltd Compounds
PE20070097A1 (es) 2005-06-28 2007-03-08 Merck Sharp & Dohme Agonistas del receptor de niacina y composiciones que contienen tales compuestos
WO2007015744A1 (en) * 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
WO2007057922A1 (en) * 2005-11-18 2007-05-24 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
EP1792901A1 (en) 2005-11-22 2007-06-06 Bayer CropScience S.A. N-(1-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides
CA2633042A1 (en) * 2005-12-20 2007-07-05 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20090062269A1 (en) 2006-02-07 2009-03-05 Subharekha Raghavan Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
EP2010512A4 (en) * 2006-04-11 2010-02-24 Merck & Co Inc NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
CN102149680B (zh) * 2008-07-08 2014-12-10 第一三共株式会社 含氮芳族杂环化合物

Also Published As

Publication number Publication date
ZA201100183B (en) 2012-06-27
HK1155443A1 (zh) 2012-05-18
US8648103B2 (en) 2014-02-11
US20140187592A1 (en) 2014-07-03
WO2010004972A1 (ja) 2010-01-14
CN102149680A (zh) 2011-08-10
JP5461398B2 (ja) 2014-04-02
RU2481330C2 (ru) 2013-05-10
JPWO2010004972A1 (ja) 2012-01-05
DK2308838T3 (da) 2016-05-17
CY1117503T1 (el) 2017-04-26
CA2730078A1 (en) 2010-01-14
TW201004950A (en) 2010-02-01
EP2308838A1 (en) 2011-04-13
EP2308838B1 (en) 2016-02-17
US20120108639A1 (en) 2012-05-03
AU2009269178B2 (en) 2012-09-06
MX2011000044A (es) 2011-02-22
PL2308838T3 (pl) 2016-08-31
ES2566529T3 (es) 2016-04-13
CO6341610A2 (es) 2011-11-21
BRPI0915473A2 (pt) 2015-11-10
SMT201600119B (it) 2016-07-01
TWI435875B (zh) 2014-05-01
RU2011104223A (ru) 2012-08-20
EP2308838A4 (en) 2012-05-09
NZ590790A (en) 2012-09-28
CN102149680B (zh) 2014-12-10
HRP20160236T1 (hr) 2016-05-06
KR20110025742A (ko) 2011-03-11
IL210498A0 (en) 2011-03-31
US9150563B2 (en) 2015-10-06
SI2308838T1 (sl) 2016-09-30
AU2009269178A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
HUE028595T2 (hu) Nitrogéntartalmú aromás heterociklil vegyület
JP4324221B2 (ja) Ｐｐａｒアゴニスト活性を有する誘導体
WO2002006237A1 (fr) Medicament comprenant un derive de dicyanopyridine
WO2004026841A1 (ja) 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
WO2006022374A1 (ja) ２－フェニルピリジン誘導体
RU2125565C1 (ru) Производные фенокси- или феноксиалкилпиперидина и антивирусная композиция на их основе
WO2016031987A1 (ja) オートタキシン阻害活性を有するピリミジノン誘導体
JP2022521825A (ja) アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法
WO2006022375A1 (ja) ２－フェニルチオフェン誘導体
TW202003472A (zh) 鈣蛋白酶(calpain)調節劑及其醫療用途
EP2455368B1 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
JP2011157349A (ja) 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
US20170107234A1 (en) Tricyclic heterocycle derivatives having hiv replication inhibitory effect
CN114206836A (zh) 新型吡咯化合物
WO2017033966A1 (ja) オートタキシン阻害活性を有する５位カルボニルアミノアルキル置換縮合ピラゾール誘導体
SG178043A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
EP2980085A1 (en) Pyrazole derivative
TW201036962A (en) Novel 2, 5-disubstituted pyrrole derivative
TW202409010A (zh) 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑